Hyper-Personalized Medicine Market Size is Projected to Generate a Revenue of $5,886.50 Billion by 2031

Download Sample   Reports Overview

The Global Hyper-Personalized Medicine Market Size is predicted to be valued at $5,886.50 billion by 2031, surging from $2,100.00 billion in 2021, at a CAGR of 11.7 %.

Impact Analysis of COVID-19 on the Hyper-Personalized Medicine Market

The COVID-19 pandemic had a moderate impact on the hyper-personalized medicine industry with both challenges and opportunities for companies and industries. On the positive side, there has been an increase in demand for personalized medicines as patients seek treatments that can be customized to their specific needs. This trend has also been driven by advancements in genomics and molecular testing, making it easier and more affordable to analyze individual patient data. However, the pandemic also created challenges for the hyper-personalized medicine market. For example, disruptions in supply chains and manufacturing processes made it difficult to produce and distribute personalized medications. There have also been delays in clinical trials and research, which may slow down the development of new treatments in the post-pandemic period. The growing demand for personalized medicines is expected to continue as patients increasingly seek customized treatment options.

Global Hyper-Personalized Medicine Market Analysis

The availability of big data is a significant driver of the hyper-personalized medicine market. With the increase in the amount of data generated from various sources such as electronic health records, genomics, and medical imaging, healthcare providers and researchers can analyze the data to identify patterns, detect diseases early, and develop targeted treatments. The use of big data analytics in healthcare allows for a more personalized approach to medicine, as it enables doctors to create treatment, including their genetics, lifestyle, and medical history. Furthermore, the use of big data in healthcare is expected to increase as more healthcare providers adopt electronic health records and patients become more willing to share their health data for research purposes. This is likely to lead to more accurate diagnoses, better treatment outcomes, and ultimately, more efficient, and cost-effective healthcare. These are the major factors anticipated to boost the hyper-personalized medicine market share during the forecast timeframe.

However, hyper-personalized medicine raises regulatory challenges. There are several hurdles involved with hyper-personalized medicines, particularly acquiring authorization for routine use from various regulatory organizations. Also, there are other challenges related to the widespread acceptance of hyper-personalized medicines among various healthcare stakeholders, including physicians, insurance companies, healthcare executives, and, ultimately, patients. The hyper-personalized medicine has the potential to revolutionize healthcare, and addressing these regulatory challenges will be critical to ensuring that these treatments are safe and effective. All these factors are anticipated to hamper the hyper-personalized medicine market growth in the upcoming years.

Increase in international adoption of genomics technologies, facilitated in part by lower costs of genotyping and whole-genome sequencing, is generating cross-cutting health care, public health, and policy concerns that transcend national borders and necessitate global health action. Genomics is the individual's complete DNA sequence and the analysis of how these sequences interact to influence health and disease.

With the advancements in genomics technology, it is now possible to obtain a complete genetic profile of an individual in a relatively short amount of time. This personalized genetic information can be used to develop targeted therapies that are customized to an individual's genetic makeup, making it possible to provide more effective treatments for various diseases. For example, oncologists can use genomic information to develop personalized treatment plans for cancer patients based on the unique genetic characteristics of their tumors. The growing adoption of genomics presents significant opportunities that is estimated to boost the hyper-personalized medicine market size during the forecast period.

Global Hyper-Personalized Medicine Market, Segmentation

The hyper-personalized medicine market is segmented on the basis of product, application, end user, and region.

Product:

The product segment is further classified into hyper personalized medicine diagnostics, hyper personalized medicine therapeutics, hyper personalized medical care, and hyper personalized nutrition and wellness. Among these, the hyper personalized nutrition and wellness sub-segment accounted for the largest market share in 2021. The hyper personalized nutrition and wellness are growing because of consumer awareness of the importance of nutrition and wellness in maintaining good health and preventing chronic diseases. Consumers are increasingly looking for personalized solutions to meet their unique needs, rather than relying on a one-size-fits-all approach. There is a growing demand for preventative healthcare, with individuals looking to maintain good health and prevent chronic diseases. Hyper personalized nutrition and wellness plans can play a key role in this, by providing personalized recommendations that are personalized to an individual's unique needs.

Application:

The application segment is further classified into oncology, neurology, blood transfusion safety, diabetes, autoimmune diseases, and cardiology. Among these, the oncology sub-segment accounted for the largest market share in 2021. Oncology is a particularly promising area for hyper-personalized medicine because cancers are caused by genetic mutations and other factors that vary widely from patient to patient. By designing treatments for each individual's unique molecular profile, hyper-personalized medicine can improve patient outcomes and reduce side effects. These therapies are designed to specifically target cancer cells while sparing healthy cells, reducing the side effects associated with traditional chemotherapy.

End User:

The end user segment is further classified into hospitals, diagnostic centers, research and academic institutes, and others. Among these, the hospitals sub-segment accounted for the largest market share in 2021, owing to the increase in demand for advanced healthcare services and personalized treatments. Hospitals are equipped with the necessary infrastructure, technology, and medical expertise to provide personalized healthcare services to patients. With the advent of genomics, proteomics, and other advanced technologies, hospitals can analyze a patient's genetic makeup, disease history, lifestyle factors, and environmental factors to develop personalized treatment plans. Moreover, hospitals have the necessary infrastructure, expertise, and resources to offer personalized medicine to patients. This creates new opportunities for hospitals to increase their market share and revenue in the hyper-personalized medicine market.

Region:

The hyper-personalized medicine market in Asia-Pacific is projected to show the fastest growth during the forecast period. The hyper-personalized medicine market is expected to grow significantly in the region due to several factors such as the rise in healthcare spending, the increase in access to healthcare, and the adoption of advanced technologies. Japan, China, and India are the major countries driving the growth of hyper-personalized medicine in Asia-Pacific. Japan has a strong healthcare system and a large population of elderly people, which makes it an ideal market for personalized medicine.

In China, the government is heavily investing in healthcare infrastructure and technology, which is expected to increase the adoption of hyper-personalized medicine. India has a growing middle class and a large population, which is expected to drive demand for hyper-personalized medicine. The country is also home to a large number of biotech and pharmaceutical companies, which are investing on R&D in the field of personalized medicine. There are factors anticipated to drive the regional market growth during the forecast period.

Key Players in the Global Hyper-Personalized Medicine Market

Some of the leading hyper-personalized medicine market players are

• QIAGEN
• Exagen Inc.
• Abbott
• Dako A/S
• GE Healthcare
• Illumina Inc.
• ASURAGEN INC.
• Exact Sciences Corporation
• Danaher Corporation (Cepheid Inc.)
• Decode Genetics Inc.   

In January 2019, in Gig Harbor, Washington, Metagenics, Inc. opened the Personalized Lifestyle Medicine Center (PLMC), a clinical research laboratory and patient clinic. The Institute will experiment with individualized lifestyle medicine, tailoring its therapy plans to each patient.